Breaking News

Monkeypox Vaccine Availability Exceeds Demand

September 27, 2022 • 10:30 am CDT
Total Monkeypox Vaccines Administered
(Precision Vaccinations News)

According to the latest monkeypox vaccine availability and administration data published by the U.S. CDC, the months-long imbalance between supply and demand may have turned positive.

As of September 26, 2022, the U.S. HHS's Administration for Strategic Preparedness and Response reported that 833,193 Jynneos® vaccines had been shipped since May 2022.

And the CDC recently confirmed that 684,980 doses had been administered in the 48 reporting U.S. Jurisdictions.

Even the monkeypox virus (MPVX) hot-spot of New York City is opening up second Jynneos vaccination appointment on a 'walk-up' basis.

This good news is matched with a slowing down of new MPVX cases confirmed by the CDC.

On September 26, 2022, the CDC reported 25,162 cases this year.

Moreover, a new non-peer-reviewed study published in Israel indicates that the Jynneos vaccination can be effective in people.

On September 23, 2022, Clalit Health Services researchers evaluated real-life vaccine effectiveness (VE) after providing one vaccine dose to individuals at risk of MPVX infection.

A total of 1,970 subjects met the study eligibility criteria (0.04% of CHS members).

Of them, 44% were vaccinated with Jynneos and completed at least 25 days of follow-up.

These researchers found the VE was estimated at 79%, but with an extensive confidence interval (24%-94%).

The two-dose Bavarian Nordic Jynneos (MVA-BN, IMVANEX®, IMVAMUNE®) vaccine was approved by the U.S. FDA on September 24, 2019.

Additional monkeypox vaccine and treatment research news are posted at Monkeypox Today.

Our Trust Standards: Medical Advisory Committee

Share